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EDITORIAL REVIEW
Disorders of renal calcium excretion
In this review clinical abnormalities of renal calcium excre-
tion will be examined against the background of our present
understanding of two interrelated areas: (1) the physiology of
normal renal calcium handling, and (2) total calcium homeosta-
sis, involving the integrated actions of the skeleton, intestine,
and endocrine systems, as well as the kidney.
Overall renal calcium handling
Under normal circumstances, the urinary excretion of calci-
um by the mammalian kidney amounts to approximately 2% of
the glomerular filtered load. Several attempts have been made
to construct a model to account for the handling of calcium by
the whole kidney. In one study [1] a reabsorptive transport
maximum (Tm) was observed for calcium (as filtered calcium
load increased, tubular reabsorption reached a maximum, be-
yond which further increments in filtered calcium load were
excreted entirely). However, other investigators have not con-
firmed the existence of a calcium Tm at plasma calcium levels
compatible with life [2, 3]. Moreover, it is clear from micro-
puncture studies that the two major tubular sites of calcium
transport, the proximal tubule and thick ascending limb of
Henle's loop, have the capacity to increase calcium reabsorp-
tion in proportion to delivery up to very high filtered loads (see
below). Clearance experiments have demonstrated that factors
such as extracellular fluid volume expansion and hypercalcemia
inhibit tubular calcium reabsorption and may contribute to the
fortuitous production of an apparent Tm. Also, in subjects with
intact parathyroid glands, varying parathyroid function may
influence the relationship between plasma calcium concentra-
tion and urinary calcium excretion.
In an analysis of whole kidney calcium handling, Mioni et a!
[4] suggested that it may reflect the sum of a fractional
component absorbing some 40% of filtered calcium (presumably
in the proximal nephron) and an absolute (Tm-limited) compo-
nent presumably located in the distal nephron. In any event the
relationship between calcium excretion and plasma (ultrafiltera-
ble) calcium concentration in subjects with normal parathyroid
glands, shows a low calcium excretion at subnormal plasma
calcium levels and a rapidly increasing absolute and fractional
calcium excretion as the plasma calcium level is raised progres-
sively above normal. Hypo- and hyperparathyroidism shift this
relationship such that, with increasing parathyroid hormone
(PTH) levels, urinary calcium excretion is lower at any given
plasma calcium concentration [5]. Thus, the parathyroid effect
permits the excretion of a variable daily calcium load despite
the maintenance of a constant plasma calcium concentration.
Calcium handling by successive nephron segments
There have been several detailed reviews of segmental calci-
um transport in recent years [6—11]. In summary, about 60% of
the plasma calcium is filtered through the glomerular capillaries
[121. Reabsorption occurs along the proximal convoluted tubule
in approximate proportion to that of sodium and water, so that
the ratio of the calcium concentration in tubule fluid to that in
plasma ultrafiltrate remains close to 1.0. The proximal tubular
epithelium is highly permeable to calcium [131. There is evi-
dence for sodium-dependent active transport of calcium in the
proximal convoluted tubule [14]. Although sodium and calcium
reabsorption normally proceed in parallel along the proximal
convoluted tubule, the reabsorption of these ions can be
dissociated experimentally by varying the anionic constituents
of luminal fluid [15]. In vitro perfusion studies of the pars recta
of the proximal tubule have recently demonstrated a net calci-
um reabsorptive rate similar to that of the proximal convoluted
tubule [16]. Calcium reabsorption was shown to be active, but
was not inhibited by ouabain, and the pars recta was less
permeable to calcium than the proximal convoluted tubule [161.
Direct studies of the thin limbs of Henle's loop have demon-
strated low calcium permeability and no active calcium trans-
port [17]. The thick ascending limb is clearly a major site of
calcium reabsorption, though there are conflicting data regard-
ing the issue of whether calcium reabsorption in this segment is
entirely voltage dependent [18—20] or whether separate active
calcium transport occurs [17, 211. PTH has been noted to
enhance [22] or not affect [19] calcium transport in this segment.
Suki et a! [23] recently observed that calcium reabsorption in
the medulary thick ascending limb is voltage-dependent, inhib-
ited by furosemide and unaffected by PTH, while in the cortical
thick ascending limb calcium transport was greater than pre-
dicted from the potential difference (PD), was unaffected by
furosemide (despite a fall in PD), and was increased by PTH
despite a lack of change in the PD. This apparent heterogeneity
within the thick ascending limb of the rabbit may partly explain
the conflicting results obtained by different investigators.
In the segments of the nephron beyond the loop of Henle,
active calcium transport occurs. In the distal convoluted tubule,
which is relatively impermeable to calcium, calcium reabsorp-
tion is stimulated by thiazide diuretics [24] and by PTH and
cyclic AMP [251. Similarly PTH has been shown to increase
calcium reabsorption in the granular portion of the cortical
collecting tubule [19]. The negative intraluminal PD in the distal
nephron segments would be predicted to retard calcium reab-
sorption or even to promote secretion; such secretion has been
observed recently in vitro [26].
Thus, calcium is reabsorbed along all segments of the neph-
ron, with the possible exception of the thin descending and
ascending limbs of Henle's loop. It is likely that most calcium
reabsorption in both the proximal convoluted tubule and the
thick ascending limb is secondary to processes mediating
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sodium transport, so that the reclamation of this portion of
filtered calcium does not require extra energy expenditure.
There is evidence, however, that independent active calcium
reabsorption may occur in the proximal convoluted tubule, the
pars recta, and the thick ascending limb as well as more distal
segments. The portion of calcium that is reabsorbed by these
separate active processes prior to the distal tubule is unclear.
Although calcium addition may occur under some circum-
stances in the distal segments, its significance is at present
unknown.
Factors influencing tubular calcium transport
Most factors with specific actions on calcium excretion
appear to exert their effects beyond the late proximal convolut-
ed tubule (Table 1).
In addition to the agents listed in Table 1, several others exert
proportionate effects on tubular sodium and calcium reabsorp-
tion, for example, alterations in extracellular fluid volume [35,
361, mannitol [37], and furosemide [17, 23, 38]. Many other
factors, including hormones (calcitonin, insulin, vitamin D) and
drugs (acetazolamide, spironolactone, triamterene), have been
found to have small effects on tubular calcium transport [8. 11],
but these are of uncertain clinical significance.
The elucidation of the distinctive actions of various diuretic
drugs on tubular calcium transport has permitted their use as
probes in attempts to understand the pathophysiology of disor-
ders of urinary calcium excretion. Acetazolamide causes a
parallel reduction of sodium and calcium reabsorption in the
proximal tubule [391, but in the final urine only sodium excre-
tion increases, so that the increased calcium delivered to the
distal tubule must be reabsorbed. It is not clear at present
whether this results from a direct effect of acetazolamide
(similar to that of thiazide) to enhance distal calcium reabsorp-
tion, or whether it is secondary, for example, to increased distal
bicarbonate delivery.
Furosemide causes an approximately parallel inhibition of
sodium and calcium reabsorption in the thick ascending limb of
Henle's loop [17, 381 which may occur in the medullary and not
the cortical portions of this segment [23]. Provided extracellular
fluid volume is maintained, furosemide causes a sustained
increase in calcium excretion.
Long-term administration of thiaside diuretics causes a re-
duction in urinary calcium excretion [40]. Now that it has been
clearly demonstrated that thiazides directly stimulate calcium
reabsorption in the distal convoluted tubule [24] it is uncertain
whether hypotheses involving enhancement of proximal calci-
um reabsorption secondary to thiazide-induced volume deple-
tion [41] still need to be invoked to explain the hypocalciuria.
The observation that saline infusion reverses thiazide-induced
hypocalciuria does not prove that volume contraction mediates
the hypocalciuria, since increased calcium excretion is an
expected effect of saline infusion irrespective of extracellular
volume status. The acute effect of thiazide, comprising no
change or a small increase in urinary calcium excretion associ-
ated with a marked natriuresis [38]. presumably represents the
net result of two opposing influences on tubular calcium reab-
sorption. The thiazide has a direct stimulatory effect on calcium
reabsorption in the distal convoluted tubule, while the marked
increase in sodium and water delivery to sites beyond the distal
convoluted tubule presumably has an inhibitory effect on calci-
Inhibiting calcium reabsorption
Hypercalcemia
Metabolic acidosis
Phosphate depletion
Hypermagnesemia
Loop segment represents the segment between late proximal and
distal convoluted tubule, and includes the pars recta, loop of Henle, and
early distal convoluted tuble.
The reference includes data that do not confirm an effect.
urn reabsorption. This acute dissociation of sodium and calcium
reabsorption by thiazide has been shown to occur in the
absence of parathyroid hormone [42].
Renal calcium excretion and total calcium homeostasis
Clinical disorders of calcium excretion cannot be understood
without reference to the other organs which play a major role in
calcium homeostasis, namely the skeleton, the intestine, and
the endocrine system, as well as the kidney. Urinary calcium
excretion must ultimately represent the sum of net intestinal
absorption and net skeletal calcium loss. For example, in
primary hyperparathyroidism, in which both net calcium loss
from bone and net intestinal calcium absorption are increased,
urinary calcium must increase.
Hypercalcemia may theoretically result from two distinct
pathophysiological mechanisms. The serum calcium may rise
because of a fall in urinary calcium excretion unassociated with
a change in input from gut and bone, or it may rise as a
consequence of increased input from gut or bone without a
change in urinary calcium excretion. In practice, however,
most clinical hypercalcemic disorders are complex, involving
changes in both net input and renal calcium transport. Further-
more, hypercalcemia may directly reduce the GFR [43] and
tubular calcium reabsorption [20], and it may cause dehydration
which further reduces the GFR.
The parathyroid glands occupy a central position in calcium
homeostasis, responding to a fall in extracellular fluid calcium
ion concentration by increasing their secretion of PTH. PTH
has several actions which together operate to elevate the
extracellular fluid calcium concentration. In concert with I ,25
dihydroxy vitamin D [1 ,25(OH)2D11, PTH promotes increased
transport of calcium out of bone [44]. In the renal tubule, PTH
enhances calcium reabsorption, reducing urinary calcium
losses, and inhibits phosphate reabsorption, causing a fall in the
Table 1. Agents with specific effects on renal calcium transport
(independent of sodium)
Site of action in
Agent nephrow Reference
Enhancing calcium reabsorption
PTH
ThiaLide
Hypocalcemia
Metabolic alkalosis (or
increased luminal
bicarbonate concentration)
Hyperphosphatemia
Thick ascending limb (19h) 20, 22, 23
Distal convoluted 19, 25
tubule
Collecting duct 19
Distal convoluted 24
tubule
'Loop segment' 27
'Loop segment' 28
Distal nephron 29
'Loop segment' 20, 30
'Loop segment' 28
'Loop segment' 31—33
'Loop segment' (2ff') 34
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plasma inorganic phosphate concentration. Both directly, and
via the fall in phosphate, PTH promotes the synthesis of
l,25(OH)2D3 in the kidney. The increased l,25(OH)2D3 produc-
tion in turn enhances intestinal calcium and phosphate absorp-
tion. The role of calcitonin in calcium homeostasis is less clear.
Talmage et al [45] recently proposed that postprandial calcito-
nm secretion promotes the storage of calcium and phosphate in
bone fluid in a labile form that is the first calcium to be
mobilized during fasting periods.
The complexity of the interactions between the bone, kidney,
intestine, and endocrine system is illustrated by the normal
circadian rhythm of calcium homeostasis (Fig. 1). During the
day ingested calcium is absorbed from the intestine and tends to
elevate the extracellular fluid calcium concentration, presum-
ably contributing to the lower PTH level that is observed by day
rather than at night [471. The lowered PTH level together with
postprandial calcitonin secretion promotes a shift in skeletal
calcium balance toward net accretion so that the readily mobi-
lized perilacunar [461 or bone fluid [45] calcium stores are
replenished. There may also be more rapid mineralization of
osteoid in bone remodelling units during the day. Urinary
calcium loss is enhanced by the decreased action of PTH on the
renal tubules. The relative amount of calcium deposited in bone
or lost into the urine will depend on the respective sensitivities
of bone and renal tubular cells to the prevailing PTH level as
well as the amount of calcium deposited into mineralizing bone.
At night, during fasting, PTH levels tend to rise. Urinary total
hydroxyproline excretion also increases at night, suggesting
increased bone resorption [48]. It has been suggested that the
labile calcium stores in bone fluid are the first to be mobilized,
perhaps requiring less PTH than bone resorptive processes [45].
Furthermore, it has been shown that prior administration of
calcium augments the action of PTH to promote calcium
transfer out of bone [49]. Therefore, during early fasting,
particularly in an individual previously on a high calcium
intake, these perilacunar stores may be mobilized in response to
a PTH level that has little effect on tubular calcium reabsorp-
tion, so that the urinary calcium losses will be considerable.
During early fasting metabolic acidosis due to ketosis may also
increase urinary calcium excretion. By contrast, in an individ-
ual on a prolonged low calcium intake, a higher PTH level is
required to mobilize skeletal mineral; this PTH level will be
sufficient to markedly reduce urinary calcium losses. Another
potential variable is the renal production of l,25(OH)2D3. PTH
is a determinant of l,25(OH)2D3 production [50], as well as
controlling the plasma inorganic phosphate concentration
which itself influences l,25(OH)2D3 secretion [51]. The rate of
I ,25(OH)2D production by the kidney in response to a given
level of PTH must therefore influence intestinal calcium absorp-
tion and urinary calcium excretion. If the skeletal or renal
tubular sensitivity to PTH were altered indisease, a change in
the relative contributions of bone, kidney, and intestine to the
maintenance of calcium homeostasis would be anticipated. It is
evident that these considerations may be relevant to the patho-
genesis of a variety of clinical disorders, including osteoporosis
and idiopathic hypercalciuria.
Some clinical aspects of renal tubular calcium transport
Glomerular disease. In chronic renal failure marked intestinal
malabsorption of calcium must lead to hypocalciuria unless it is
offset by a large increase in net calcium loss from bone. In mild
to moderate renal failure (GFR> 10 ml/min) both absolute and
fractional urinary calcium excretion are usually decreased,
whereas in severe renal failure fractional calcium excretion
rises [521. By contrast fractional sodium excretion is increased
at all levels of renal failure. The mechanism of this increase in
fractional sodium excretion is not completely understood, but
the striking correlation between fractional sodium and calcium
excretions in severe renal failure [53] suggests that tubular
reabsorption is impaired at sites at which both ions are reab-
sorbed in parallel, such as the proximal tubule and/or loop of
Henle. The relative decrease of fractional calcium excretion in
early renal failure probably reflects the stimulatory effects of
secondary hyperparathyroidism and hypocalcemia on calcium
reabsorption. In severe renal failure these effects may be
swamped by the increased delivery to distal reabsorptive sites
resulting from increased filtered load per nephron and reduced
reabsorption . at more proximal sites. In addition metabolic
acidosis, when it develops in severe renal failure, may directly
inhibit calcium reabsorption [54] and blunt the hypocalciuric
effect of high PTH levels [55].
Hypocalciuria has been observed in patients with the ne-
phrotic syndrome [56]; several factors may contribute to this.
The plasma ionized calcium concentration tends to be low in
this condition, perhaps in part as a result of urinary vitamin D
losses [57, 58]. Although vitamin D deficiency decreases the
effect of PTH on the skeleton, it probably does not diminish the
action of the associated secondary hyperparathyroidism to
enhance tubular calcium reabsorption.
Primary hyperparathyroidism
It is frequently stated that, because of the hypocalciuric effect
of PTH, the urinary excretion of calcium tends to be lower for
any given level of hypercalcemia in primary hyperpara-
thyroidism than in other hypercalcemic disorders. Clinical
evidence to support this statement is difficult to find [59].
Patients with only trivial hypercalcemia due to primary hyper-
parathyroidism may have marked hypercalciuria. For example,
a patient with a plasma calcium concentration of 5.25 mEq/liter
may have a urinary calcium excretion of 20 mEq/day compared
with a normocalcemic subject (plasma calcium 4.75 mEq/liter)
with a normal urinary calcium excretion of 10 mEq per day.
Assuming 60% ultrafilterability of plasma calcium, and a normal
GFR of 170 liters/day in both subjects, the hyperparathyroid
patient has an increased absolute tubular calcium reabsorption
(515.5 vs. 474.5 mEq/day) but a decreased fractional tubular
calcium reabsorption (96.3 vs. 97.9%).
Several factors may oppose the hypocalciuric effect of PTH
in primary hyperparathyroidism, by inhibiting tubular calcium
transport. These include hypercalcemia [20], hypophosphate-
mia [31—33], and possibly 1,25(OH)2D3, which may, under
certain circumstances, directly promote hypercalciuria [60].
The suggestion has been made that some patients with apparent
primary hyperparathyroidism, perhaps especially those with
very long histories of recurrent stone formation, may originally
have had so-called renal hypercalciuria which would be predict-
ed to cause secondary hyperparathyroidism and might eventu-
ally evolve into autonomous (so-called tertiary) hyperpara-
thyroidism. In such patients an intrinsic tubular absorptive
defect for calcium would account for their gross hypercalciuria
while hyperparathyroid and persisting hypercalciuria would be
expected after correction of the hyperparathyroidism, as has
occasionally been documented [61]. It is not clear, however,
whether this sequence of events ever actually occurs.
The relationship of hypercalciuria and renal calculi to altered
vitamin D metabolism has been examined in two recent studies
[62, 631 (Table 2). The basis for subdividing the patients was
different. In the study of Broadus et al [621 patients were
classified as 'absorptive' or 'nonabsorptive' on the basis of their
calciuric response to an oral calcium load. The 'absorptive'
group included a significantly larger percentage of patients with
renal calculi and had a higher mean plasma I ,25(OH)2D3 level
than the 'nonabsorptive' group. However, in the study of Pak et
al [63], patients with renal calculi did not have higher
1,25(OH)2D3 levels than those without calculi. It is not possible
to conclude, at the present time, whether different plasma
1,25(OH)2D3 levels are responsible for the different clinical
presentations of primary hyperparathyroidism, that is, with or
without renal calculi, and with or without bone disease [63].
Familial hypocalciuric hypercalcernia (FHH)
This disorder resembles primary hyperparathyroidism but
differs in its earlier age of onset, relative lack of clinical
problems including renal calculi, and markedly lower urinary
calcium excretion rates [64—671. In addition plasma magnesium
concentrations tend to be higher, and fractional urinary magne-
sium excretions lower than in primary hyperparathyroidism.
The diagnosis should be suggested by the presence of a family
history and the finding of a ratio of renal calcium clearance to
renal creatinine clearance below 0.01 [67]. The pathophysiology
of this disorder is poorly understood. The hypocalciuria is
apparently not attributable to differences in ultrafilterability of
the plasma calcium, or to differences in the GFR or PTH levels
[65]. There are conflicting data on whether there is an altered
responsiveness of renal tubular calcium transport to endoge-
nous or exogenous PTH in this disorder [68, 69]. Recently the
hypocalciuria has been shown to be present even after pre-
sumed total parathyroidectomy, suggesting that it is not due to
hypersensitivity to the enhancing effect of PTH on calcium
reabsorption [70]. In these studies the slope of the relationship
between urinary calcium excretion and plasma calcium concen-
tration remained lower after parathyroidectomy in FHH
patients than after parathyroidectomy for primary
hyperparathyroidisni.
In preliminary studies we have compared the responses of
patients with FHH and primary hyperparathyroidism to intra-
venous infusions of sodium bicarbonate, chlorothiazide, and
furosemide [71]. Patients with both disorders showed the ex-
pected acute dissociation of calcium from sodium transport in
response to bicarbonate and chlorothiazide. However, in re-
sponse to furosemide, the relative hypocalciuria in FHH was
abolished; calcium excretion increased to a similar level in
FHH and primary hyperparathyroidism. Since furosemide in-
hibits calcium reabsorption in Henle's loop, this observation is
consistent with a site in Henle's loop for the enhanced calcium
reabsorption that is typical of FHH. Such an enhancement of
calcium transport in the thick ascending limb could result from
a selective increase in calcium permeability in this segment, or
from a lack of the normal inhibitory effect of hypercalcemia on
loop calcium transport [20]. The lack of an inhibitory effect of
hypercalcemia on magnesium reabsorption at this site, ob-
served in some studies [7] but not others [20] could also account
for reduced fractional magnesium excretion in this disorder. In
the original report of this condition by Foley et al [73], the
response to oral furosemide was examined. Only a transient
increase in urinary calcium excretion was observed. However,
it is possible that in this chronic study, volume depletion may
have offset an effect of furosemide on calcium reabsorption in
Henle's loop.
Idiopathic hypercalciuria
Idiopathic hypercalciuria, an increase in urinary calcium
excretion rate in the absence of hypercalcemia, occurs with
greater frequency in patients forming renal calcium oxalate
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Day Night
PTH
Fig. 1. Diagrammatic representation of
circadian changes in calcium homeostasis
(partly speculative). During the day, intestinal
calcium absorption is associated with a higher
serum calcium level, calcium deposition in the
skeleton, relative parathyroid suppression,
and higher urinary calcium losses. At night the
serum calcium is lower, PTH is higher, and
calcium is released from the skeleton, but
urinary losses are reduced.
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Table 2. 1,25(OH)2D3 levels in subpopulations of patients with primary hyperparathyroidism
Reference Subgroup N
Plasma
I ,25(OH)2D3 Serum calcium GFR
pg/mi mg/dl mi/mm
61 1 'Absorptive' 30 63 90 11.0 91
2 'Nonabsorptive' 20 15a 57a 11.3 100
62 1 Renal calculi 32 100 68 11.2 93
2 No renal calculi 37 Oa 62 11.3 87
Abbreviations: N, number of patients; GFR, glomerular filtration rate; 'absorptive', an increase in urinary calcium of more than 0.20mg calcium
per deciliter of glomerular filtrate during the second hour following 1000 mg oral calcium.
a Number shown indicates a significant difference between 1 and 2, P < 0.05.
stones than in normal control subjects [59, 74—761. For clinical
purposes many investigators have used the arbitrary criterion of
a daily urinary calcium excretion of greater than 300 mg in men
or 250 mg in women ingesting their normal diets to identify
idiopathic hypercalciuria. Diet is obviously important, since
urinary calcium increases with dietary calcium both in normal
subjects and in renal stoneformers. Other dietary constituents
including sodium and vitamin D may also affect urinary calcium
excretion.
The principal source of the increased urinary calcium in
idiopathic hypercalciuria is the intestine and there is a tendency
to a small overall negative calcium balance [761. Major current
controversies regarding the pathophysiology of idiopathic hy-
percalciuria include (1) the cause of the enhanced alimentary
calcium reabsorption and (2) the issue of whether alimentary
calcium hyperabsorption is the primary abnormality, leading to
secondary hypercalciuria, or whether renal calcium wasting is
primary, and the calcium hyperabsorption secondary.
l,25(OH)2D3 is the principal known regulator of calcium
absorptive capacity. Mean plasma I ,25(OH)2D3 levels were
reported to be higher in idiopathic hypercalciuric patients than
in normal control subjects [77—791. However, in these studies
only a minority of patients actually had plasma 1 ,25(OH)2D3
levels above the normal range, and in so-called absorptive
hypercalciuria, intestinal calcium absorption did not correlate
with 1 ,25(OH)2D3 levels. Furthermore, dietary calcium intake,
which influences l,25(OH)2D3 levels [801, was not controlled in
some of these studies. In two recent studies [81, 821 plasma
l,25(OH)2D3 levels were not significantly different in renal
stoneformers and normal control subjects either while they
were ingesting free diets or in response to severe dietary
calcium restriction. Thus the role of increased l,25(OH)2D3
production in mediating intestinal calcium absorption in idio-
pathic hypercalciuria is not, at present, clear. The possibility
that intestinal hyper-responsiveness to normal plasma
l,25(OH)2D3 levels may be the cause of alimentary calcium
hyperabsorption in some stoneformers has not been excluded.
Several authorities [72, 731 have maintained that the intestinal
abnormality is usually primary in idiopathic hypercalciuria. By
contrast Jackson and Dancaster [83] suggested that renal calci-
um wasting was primary and intestinal calcium hyperabsorption
was compensatory and secondary. Recently, several investiga-
tors favored this latter interpretation of their data [59, 81, 82,
84, 85]. It has also been suggested that there may be two (or
more) quite distinct pathophysiological varieties of idiopathic
hypercalciuria including the primarily alimentary and the pri-
marily renal [61, 751.
It has been argued that a primary renal calcium 'leak' would
tend to lower the plasma calcium concentration and hence lead
to elevated PTH and urinary cyclic AMP levels. Pak [75]
defined a small proportion of his patients with idiopathic
hypercalciuria who have a high urinary calcium excretion rate
following an overnight fast and conform to the above predic-
tions. Since PTH normally reduces urinary calcium excretion,
these subjects must have either reduced effective PTH levels or
a resistance to the hypocalciuric action of PTH. Unfortunately,
reported PTH levels in idiopathic hypercalciuria have varied,
probably depending on which PTH assay is used. Not only is
the baseline PTH level likely to be an important determinant of
urinary calcium excretion, but the rapidity with which PTH
levels and their hypocalciuric effect wane postprandially in
response to a small rise in plasma calcium concentration
presumably influences the partition of absorbed calcium be-
tween the skeletal stores and the urine [86]. Burckhardt and
Jaeger [87] recently reported generally normal PTH and urinary
cyclic AMP levels in apparently 'renal' hypercalciuria. They
therefore suggest that a mechanism other than secondary
hyperparathyroidism must be responsible for the enhanced
intestinal calcium absorption associated with renal hypercal-
ciuria. A subtle renal abnormality whereby a given PTH level
exerted a smaller than normal hypocalciuric effect but induced a
greater than normal synthesis of 1 ,25(OH)2D3 in the kidney
could contribute to hypercalciuria of both 'renal' and 'absorp-
tive' types.
A defect in renal tubular calcium reabsorption such as has
been proposed in idiopathic hypercalciuria could result from a
reduction in the normal hypocalciuric action of PTH, or it could
be independent of PTH. Furthermore, it could result either
from a reduction in the active transport of calcium in the renal
tubule, or from an increased backleak of calcium as a result of
altered tubule permeability, for example, in the cortical collect-
ing duct [26] where the negative intraluminal PD would favor
calcium addition to the urine.
Evidence for a defect in renal tubular calcium reabsorption
has been provided by Muldowney, Freaney, and Ryan [88] who
have shown that hypercalciuric patients do not have an abnor-
mal rise in total or ionized plasma calcium levels following an
oral calcium load, and yet they have an abnormal increase in
urinary calcium excretion rate. These patients had decreased
fasting PTH levels. The data do not clarify whether or not the
reduced PTH levels may have contributed to the
hypercalciuria.
Peacock and Nordin [31 examined the relationship between
plasma and urinary calcium during calcium infusion in normal
With renal
calculi %
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subjects and patients with idiopathic hypercalciuria. They
found a rather variable relationship in both groups, and they
were not statistically different.
As an alternative approach to try to show differences in renal
tubular function between stoneformers and normal subjects,
responses to single oral doses of diuretic drugs were compared
[84]. Calcium stoneformers showed significantly increased in-
crements in sodium, calcium, and magnesium excretion com-
pared with normal control subjects in response to hydrochioro-
thiazide but a decreased natriuresis in response to acetazolam-
ide, These abnormalities were most prominent in patients with
hypercalciuria during fasting. These findings were felt to be
consistent with an impairment of proximal fluid reabsorption in
the stoneformers. This would cause increased delivery of
sodium, calcium, and magnesium to the distal tubule where the
excess sodium and magnesium, but not calcium, are presum-
ably reabsorbed, since these patients have normal sodium and
magnesium excretions associated with hypercalciuria. In this
event, an exaggerated response would be anticipated to an
agent such as hydrochlorothiazide that inhibits distal tubular
reabsorption.
If such a proximal defect is present in many calcareous
stoneformers, it would cause increased calcium delivery to the
distal nephron and presumably an increased risk of precipita-
tion of insoluble calcium salts. Furthermore, the hypophospha-
temia commonly observed in calcium stoneformers may be
another consequence of such a proximal tubule impairment,
since the proximal tubule is the major site of phosphate
reabsorption. It is not clear, however, whether such a renal
tubular defect is primary in many or most calcareous stone-
formers, or whether it may be in some way secondary to
humoral or other factors.
Further evidence for a primary abnormality of renal calcium
reabsorption, associated with defective renal phosphate and
magnesium conservation, has been provided by the recent
study of Coe et al [80]. In this study patients with idiopathic
hypercalciuria were placed on very low calcium intakes and
continued to excrete more calcium in the urine than was
provided by the diet for more than 1 week. Urinary phosphate
and magnesium were also increased in comparison with normal
subjects. In this study PTH levels were significantly lower in
the stoneformers than in the normal subjects. Of particular
interest, serum calcium levels were similar in normals and
patients on free diets, but on the very low calcium diet, serum
calcium fell in the normal subjects but increased in the stone-
formers. This latter observation is difficult to reconcile with a
simple primary defect in renal calcium reabsorption, but it is
consistent with an enhancement of skeletal calcium mobiliza-
tion in response to dietary calcium deprivation in stoneformers
in comparison with normal subjects, which cannot be attributed
to increased parathyroid activity, and indeed may be responsi-
ble for the reduced PTH levels that were observed in the
stoneformers.
Metabolic acidosis and alkalosis
As indicated in Table 1, metabolic acidosis is associated with
the inhibition of tubular calcium reabsorption [28, 891. A recent
preliminary study suggests that, in addition to a PTH-indepen-
dent effect, acidosis may inhibit the effect of PTH on calcium
reabsorption [55]. Metabolic alkalosis is associated with en-
hanced calcium reabsorption, and recent evidence [901 suggests
that increased luminal bicarbonate concentration may enhance
calcium reabsorption independently of systemic alkalosis. As
recently discussed by Lernann, Adams, and Gray [91], the
enhancement of tubular calcium reabsorption resulting from
increased bicarbonate delivery to the distal nephron may in part
account for the reduced incidence of hypercalciuria and renal
calculi in proximal (type 2) renal tubular acidosis when com-
pared with distal (type 1) renal tubular acidosis [92]. In distal
renal tubular acidosis, the unopposed effect of systemic meta-
bolic acidosis to decrease tubular calcium reabsorption presum-
ably contributes to the hypercalciuria. The source of the
increased urinary calcium excretion in ammonium chloride
induced acidosis in humans is increased net bone resorption
[931.
The excessive ingestion of calcium salts may lead to hyper-
calcemia and azotemia, particularly when accompanied by the
ingestion of absorbable alkalis [941 or when taken in the form of
alkalinizing calcium carbonate [95]. It is possible that the
accompanying alkalosis (or the decreased tendency to metabol-
ic acidosis) in such azotemic patients promotes tubular calcium
reabsorption and exacerbates the tendency to hypercalcemia.
Other nutritional influences on urinary calcium excretion
A high dietary protein intake results in an increased urinary
calcium excretion rate, which is associated with negative calci-
um balance [96] and is therefore presumably derived from bone.
This effect may result from the increased acid production and
excretion that accompanies high protein intake [91]. There is
evidence that the incidence of renal calculi has been increasing
in the western world during the last 30 years. The only
consistent dietary correlate with stone incidence is a high intake
of animal protein, which increases urinary calcium, oxalate and
uric acid, all of which are risk factors for calcium stone
formation [97].
Glucose administration causes a rise in urinary calcium
excretion rate, which results from reduced tubular calcium
reabsorption [98]. This effect is exaggerated in patients with
calcium nephrolithiasis [99] and appears to be mediated by
insulin [100]. The clinical significance of this phenomenon is
uncertain.
As noted in Table I, severe phosphate depletion causes a
reduction in tubular calcium reabsorption and hypercalciuria
[3 1—331. The increased urinary calcium is derived partly from
increased intestinal absorption, mediated by increased
1,25(OH)2D3 levels [101], and partly from skeletal resorption
[1011. Hypercalciuria has been observed in severe dietary
phosphate deprivation in humans [1021; it is uncertain whether
or not the milder degree of hypophosphatemia that occurs in
primary hyperparathyroidism, idiopathic hypercalciuria, or dis-
tal renal tubular acidosis contributes to the hypercalciuria in
these disorders.
During prolonged fasting, despite zero calcium intake, uri-
nary calcium excretion rate remains considerable, averaging
more than 200 mg/day during 60 days of fasting in obese male
subjects [103]. This calcium must be derived from the skeleton.
Presumably the metabolic acidosis and ketosis of fasting con-
tribute to these calcium losses; however, despite a return of
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blood pH and bicarbonate to normal after 25 days of fasting, the
urinary calcium losses persisted, suggesting that other factors
are involved.
Total parenteral nutrition may be associated with gross
hypercalciuria [1041, greatly in excess of the parenteral delivery
of calcium. In these patients calcium balance was clearly
negative, osteomalacia was present on bone biopsy and hyper-
calcemia was frequent. Metabolic acidosis was not present in
these patients, though it may occur during total parenteral
nutrition. Plasma 25(OH)vitamin D levels were normal, but
after discontinuation of vitamin D administration, urinary calci-
um excretion decreased. It is not clear whether this unusual
bone disease and the associated hypercalciuria were induced by
vitamin D, its metabolites, or some other unrecognized factor
[1041.
Clinical uses of diuretics to alter urinary calcium excretion
The hypercalciuric effect of furosemide is well recognized, as
is the use of this drug in the treatment of hypercalcemia [1051. It
has not been clearly shown that a given natriuresis resulting
from furosemide administration is associated with a greater
urinary calcium excretion than a similar natriuresis due to saline
infusion. However, the use of furosemide allows the achieve-
ment of high fractional excretions of sodium without the risk of
pulmonary edema that is associated with massive saline infu-
sions alone.
The hypocalciuric effect of chronic thiazide administration is
also well known and widely exploited in treating hypercalciuria
and renal calcium stones [1061. Studies [106—109] have suggest-
ed that chronic treatment with thiazides is highly effective in
reducing the incidence of calcium containing renal calculi both
in the presence and absence [106] of hypercalciuria. One recent
controlled study, however, failed to confirm this beneficial
effect of thiazides [110]. During treatment with thiazide diuret-
ics, the chance of stone recurrence has recently been shown to
be lower in those patients showing a greater reduction in
urinary calcium excretion rate and a greater increase in urine
volume compared with their pretreatment values [111].
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